Chimeric antigen receptor（CAR）T cell therapy is a new immunotherapy in the field of tumors. Due to the immunosuppressive microenvironment and antigen expression of solid tumors，CAR⁃T treatment in solid tumors faces many challenges. Increasing evidences indicated that treatment with CAR ⁃T cells could significantly improve the prognosis and thus promising. However，the real characteristics and mechanism of CAR ⁃T cell com⁃ bined immunomodulators are not clear. This paper reviews the current situation and research progress of CAR ⁃ T cell combined immune modulators in solid tumors. We discuss the key principles of the combination strategy，sum⁃ marize the existing preclinical and clinical studies，and discuss the immune checkpoint inhibitors，interferon gene stimulating agonists，lenalidomide combined with CAR⁃T cells，and future prospects and challenges，aiming at exploring the benefit of more cancer patients.